Efficacy of Combination Therapy Sofosbuvir, Daclatasvir and Ribavirin in Patients of Hepatitis C

Abstract

Aim: To determine the effectiveness of antiviral drugs such as sofosbuvir, daclatasvir and ribavirin in hepatitis C patients and frequency of complications associated to antiviral therapy. Study Design: Prospective study. Place and Duration: This study was conducted at the department of Gastroenterology and General Medicine AK CMH / Sheikh Khalifa bin Zaid Al Nahyan Hospital Rawalakot Azad Kashmir for one year duration from 5th July 2020 to 5th July 2021. Methodology: 150 patients of both genders presented with hepatitis C were included. Patient’s ages were ranging from 25 to 70 years. After taking informed consent from all the patients, detailed medical history including age, sex, residence and education were recorded. Quantitative PCR test was obtained before starting the antiviral therapy, kit method was used. Treatment response was examined after completion of therapy. All the statistical data was analyzed by SPSS 24.0. Results: 88 (58.67%) patients were males while 62 (41.33%) patients were females. Mean age of patients was 48.52±9.38 years. At the end of treatment, 132 (88%) patients were cured and 15 (10%) patients were not cured, 3 (2%) patients had lost to follow-up. Complications associated to therapy were noted as anemia, ascites, hepatic encephalopathy and liver cirrhosis in 40 (26.67%), 20 (13.33%), 7 (4.67%) and 6 (4%) patients respectively. Conclusion: Combination antiviral therapy with Sofosbuvir, daclatasvir and ribavirin shows better results in patients with Hepatitis C with 88% cure rate. Anemia was the most frequent complication found at end of therapy. Keywords: Hepatitis C, Sofosbuvir, Daclatasvir, Ribavirin